E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008908 |
E.1.2 | Term | Chronic heart failure |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective is to investigate the safety and efficacy of vitamin D administration in patients with stable CHF. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to evaluate the effect of vitamin D administration on echocardiographic parameters of left ventricular (LV) function and N-Terminal-pro-Brain Natriuretic peptide (NT-proBNP.) Monitoring of safety endpoints including vital signs, physical examination, and laboratory analyses, biochemical indices of kidney function and bone homeostatis. (Serious) adverse event monitoring. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
The study population will consist of patients with chronic heart failure (NYHA Class II), ≥ 18 years of age with LVEF ≤ 45 %.
Inclusion criteria • Out patients ≥ 18 years of age, male or female. • Patients with a diagnosis of chronic heart failure (NYHA Class II) • LVEF ≤ 45% at visit 1 (local measurement, measured within the past 6 months assessed by echocardiogram, MUGA or ventricular angiography) • Patients must be treated with an ACE-i at a stable dose (at least enalapril 10 mg daily or any other ACE-i, e.g. ramipril, quinapril, lisinopril, fosinopril, perindopril, trandolapril; on equivalent doses, or maximum tolerated dose) or if intolerant to ACE-i with ARB therapy (Candesartan 8 mg daily or any other ARB in equivalent dose, or maximum tolerated dose) for at least 4 weeks prior to visit 1. • Patients must be treated with a beta blocker unless contraindicated or not tolerated at a stable dose for at least 4 weeks prior to visit 1 (for patients not on target dose or in absence of that medication, the reason should be documented). • Patients must not be treated with an aldosteron receptor antagonist. |
|
E.4 | Principal exclusion criteria |
Exclusion criteria • Concomitant use of ACEi and ARB. • Use of aldosteron receptor antagonist. • History of hypersensitivity to any of the study drugs. • Patients with phenylketonuria. • Patients with fructose intolerance. • Current acute decompensated heart failure. • Hypercalcemia (>2.65 mmol/l, corrected for albumin). • Hypercalciuria. • Estimated glomerular filtration fraction (GFR) between 30 and 60 ml/min/1.73m2 as measured by the modified of diet in renal disease (MDRD) formula. • Nephrolithiasis. • Sarcoidosis. • Use of the following medication: corticosteroids, thyroxin, anti epileptic drugs, tetracyclines, quinolones • Intake of supplements containing vitamin D and/or calcium. • Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or major vascular surgery, percutaneous coronary intervention (PCI) or carotid angioplasty, within the past 3 months. • Coronary or carotid artery disease likely to require surgical or PCI. • Right heart failure due to severe pulmonary disease. • Diagnosis of peripartum or chemotherapy induced cardiomyopathy within the last year. • Patients with a history of heart transplant or who are on a transplant list or with LVAD device (left ventricular assistance device). • Documented ventricular arrhythmia with syncopal episodes within past 3 months that is untreated. • Documented history of ventricular tachycardia or ventricular fibrillation without ICD (internal cardiac defibrillator). • Symptomatic bradycardia, or second or third degree heart block without a pacemaker. • Implantation of a CRT (cardiac resynchronization therapy) device within prior 3 months. • Presence of hemodynamically significant mitral and /or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation. • Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic stenosis. • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs. • Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase. • Primary liver disease considered to be life threatening. • Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months prior to Visit 1. • History or presence of any other diseases (i.e. including malignancies) with a life expectancy of < 5 years. • Current double-blind treatment in heart failure (HF) trials. • Participation in an investigational drug study at the time of enrollment or within the past 30 days or 5 half lives of enrollment whichever is longer. • Any surgical or medical condition that in the opinion of the investigator or medical monitor would jeopardize the evaluation of efficacy or safety. • History of noncompliance to medical regimens and patients who are considered potentially unreliable. • Pregnant or lactating women. • Treatment with any of the following drugs within the past 4 weeks prior to Visit 1 (T0): direct renin inhibition including Aliskiren and intravenous vasodilator and/or inotropic drugs. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of this study is the plasma renin activity after 6 weeks of treatment with vitamin D compared to the PRA after 6 weeks without treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
This is provided in the protocol. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |